Abstracts Archive - Page 380 of 2425 - ACR Meeting Abstracts

Abstract Number: 1433 • ACR Convergence 2022
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Marco Matucci-Cerinic⁴, Eugenio Chamizo Carmona⁵ and Janet Addison⁶, ¹JLU Campus KK, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Cambridge University, Cambridge, United Kingdom, ⁴University of Florence, Florence, Italy, ⁵Hospital de Mérida, Mérida, Spain, ⁶Biogen Idec Ltd, Maidenhead, United Kingdom
Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…
Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Anna Dryja¹, Anna Lucia Buccarello², Isabelle Gaillard² and Joëlle Monnet², ¹MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, ²Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
Abstract Number: 1431 • ACR Convergence 2022
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Karen E Hansen¹, Mahta Mortezavi², Edward Nagy³, Cunshan Wang⁴, Carol A Connell⁴, Zaher Radi⁵, Heather J Litman⁶, Giovanni Adami⁷ and Maurizio Rossini⁷, ¹Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pfizer Inc, New York, NY, ³Pfizer Ltd, Tadworth, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
Abstract Number: 1427 • ACR Convergence 2022
Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
Ronald van Vollenhoven¹, Andrea Rubbert-Roth², Stephen Hall³, Ricardo Xavier⁴, Anna K Shmagel⁵, Yanna Song⁵, Samuel Anyanwu⁵ and Vibeke Strand⁶, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ³Emeritus Research and Monash University, Melbourne, Australia, ⁴Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁵AbbVie, Inc., North Chicago, IL, ⁶Stanford University School of Medicine, Stanford, CA
Background/Purpose: The phase 3 SELECT-CHOICE trial of patients with rheumatoid arthritis (RA) and prior inadequate response to biologic DMARD(s) (bDMARD-IR) demonstrated superiority of the JAK…
Abstract Number: 1378 • ACR Convergence 2022
Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort
Ha-Seul Jeoung¹, Kuan Liu¹, Roberta Berard², Wes Fidler³, Janet Pope⁴, Johannes Roth⁵, Carter Thorne⁶, Earl Silverman⁷ and Deborah Levy⁸, ¹University of Toronto, Toronto, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Ottawa, Ottawa, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: The long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care is not well documented. The present study aims to fill…
Abstract Number: 1410 • ACR Convergence 2022
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Ricardo Blanco⁴, Miguel Angel Gonzalez Gay⁵ and Alfonso Corrales⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Lugo, Spain, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
Abstract Number: 1423 • ACR Convergence 2022
Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Regan Arendse¹, Proton Rahman², Philip Baer³, Derek Haaland⁴, Dalton Sholter⁵, Odalis Asin-Milan⁶, Meagan Rachich⁷, Emmanouil Rampakakis⁸, A. Marilise Marrache⁹ and Allen J. Lehman¹⁰, ¹Community Rheumatology Care, Saskatoon, Canada, ²Memorial University, St. John's, NL, Canada, ³Baer Weinberg MPC, Scarborough, ON, Canada, ⁴The Waterside Clinic, Oro Medonte, ON, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Janssen Canada, Laval, QC, Canada, ⁷Janssen Inc., Guelph, ON, Canada, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with…
Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Diego Cabrera¹, Clara Wong², Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh¹, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
Abstract Number: 1387 • ACR Convergence 2022
Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
Ran Jin¹, Megan Hughes², Emily Goddard², James Piercy², Delphine Courmier², Rachael Meadows² and Waldemar Radziszewski¹, ¹Amgen, Inc., Thousand Oaks, CA, ²Adelphi Group, Bollington, United Kingdom
Background/Purpose: ABP 501 is the first adalimumab biosimilar approved by the European Medicines Agency. A clinical trial demonstrated biosimilarity between ABP 501 and the reference…
Abstract Number: 1434 • ACR Convergence 2022
Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
YoungEun Kim¹, Soo Min Ahn¹, Ji Seon Oh², Yong Gil Kim¹, Chang Keun Lee¹, Bin Yoo¹ and Seokchan Hong¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Neutropenia has been reported as one of the most frequent adverse events of tocilizumab. We conducted a retrospective cohort study to determine the risks…
Abstract Number: 1419 • ACR Convergence 2022
Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Rieke Alten¹, Gerd Burmester², Marco Matucci-Cerinic³, Andrew Ostor⁴, Liliana Zaremba-Pechmann⁵, Tamas Treuer⁶, Khai Jing Ng⁶, Jens Gerwien⁶, Kathryn Gibson⁷ and Bruno Fautrel⁸, ¹SCHLOSSPARK KLINIK, University Medicine Berlin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Florence, Florence, Italy, ⁴Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia, ⁵HaaPACS GmbH, Schriesheim, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁸Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment. Baricitinib…
Abstract Number: 1315 • ACR Convergence 2022
Building Stronger Bones: Optimizing Osteoporosis Screening at a Primary Care Clinic
Rebecca Pietro¹, Shu Min Lao¹ and Geeta Varghese², ¹Mount Sinai Morningside West, New York, NY, ²Ryan Chelsea Clinton Clinic, New York, NY
Background/Purpose: Osteoporosis is a silent disease characterized by low bone mass and deterioration of bone quality, affecting 25% of women.1 The United States Preventive Services…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1398 • ACR Convergence 2022
Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
Jian-Zi Lin, Li-Juan Yang, Hong-Gui Li, Ai-Qi Zeng, Kui-Min Yang and Lie Dai, Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Associations between rheumatoid arthritis (RA) and reduced skeletal muscle have been studied, and we firstly reported myopenia independently predict one-year radiographic progression in RA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].